A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.
about
Melanoma: from melanocyte to genetic alterations and clinical optionsSUMOylation-Mediated Regulation of Cell Cycle Progression and CancerUpdate in genetic susceptibility in melanomaRole of HIPK2 in kidney fibrosisActivators of G protein signaling in the kidneyMelanoma. Shall we move away from the sun and focus more on embryogenesis, body weight and longevity?The melanocyte lineage in development and diseaseHypoxia-independent drivers of melanoma angiogenesisThe metabolic basis of kidney cancerMelanoma: from mutations to medicineRestricted leucine zipper dimerization and specificity of DNA recognition of the melanocyte master regulator MITFDetecting endogenous SUMO targets in mammalian cells and tissues.Sumoylation in gene regulation, human disease, and therapeutic action.Metabolic rewiring in melanomaUV signaling pathways within the skinHypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cellsA variant in FTO shows association with melanoma risk not due to BMIThe next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy responseHIF1α and HIF2α independently activate SRC to promote melanoma metastasesMolecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation.SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells.Novel roles for the MiTF/TFE family of transcription factors in organelle biogenesis, nutrient sensing, and energy homeostasisSUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression.Melanoma genetics.Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches.Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer.Genetics of familial melanoma: 20 years after CDKN2A.Replication and predictive value of SNPs associated with melanoma and pigmentation traits in a Southern European case-control studyDriver mutations in melanoma: lessons learned from bench-to-bedside studiesMITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells.Loss of CITED1, an MITF regulator, drives a phenotype switch in vitro and can predict clinical outcome in primary melanoma tumours.MITF in melanoma: mechanisms behind its expression and activity.Molecular characterization of melanoma cases in Denmark suspected of genetic predispositionVariants of SCARB1 and VDR Involved in Complex Genetic Interactions May Be Implicated in the Genetic Susceptibility to Clear Cell Renal Cell CarcinomaIdentification of c-MYC SUMOylation by mass spectrometry.Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.Nephron-sparing surgery for multifocal and hereditary renal tumors.Sumoylation of transcription factor Gcn4 facilitates its Srb10-mediated clearance from promoters in yeastMolecular genetics and cellular features of TFE3 and TFEB fusion kidney cancersDelving into somatic variation in sporadic melanoma.
P2860
Q21284811-205508ED-9081-4D58-9A4F-751A737045BDQ26776081-2158D5A4-7C5F-405F-BC6F-E03141975C5DQ26778756-67268A31-AB35-43A2-9C2A-E5E9A5982E80Q26796620-18BA2F5C-0E78-422B-A35B-E063A1B05C19Q26824228-24E4C044-0AA1-4A3D-85A8-C74154F41A22Q26853315-F6BE9432-C5CD-4400-A533-E4F6A4D8765EQ26853648-E24EA82C-26CF-47EE-B56E-49663AE78E10Q27022246-3E375642-DC5F-46BC-816D-46A7C4809F73Q27023273-90052FBC-054D-4385-99AF-B6767013BF9BQ27024061-D068CE16-CAA6-4738-95A4-B949682ED139Q27675347-BF8DA7C7-776F-48C0-AAAB-510E079047E3Q27865266-CAF0C6F8-B634-4572-AC4F-379364F0D9FDQ27865271-8D89A8FB-AC30-461C-82EF-9941408B3D20Q28069081-9755BCBF-596B-4389-8D7B-E79039F3FCE8Q28238732-C27BBD20-B33A-45A5-8342-4143F3EC21F1Q28393898-51C6BCA4-165F-4CD8-A1FC-9EF0E3FDE906Q29417157-5D7E9A0E-AF32-4AC5-BF44-20FD8F7ED5A2Q30384301-13F3F4EA-239A-4CFF-91E3-D20E20D170C2Q30539170-F984EE60-F037-4B22-8806-222423CA16AAQ33560698-AB90812D-CFDE-429F-B4E5-DA9CDB4EACE8Q33688529-B0E69A8A-4179-4A3D-9C36-82FC4DC8E91AQ33756641-7F1F1CCE-9B6D-4CF8-A311-CBBDF1591A18Q33876908-A5A99730-70BC-489F-AD96-EECA060C70B0Q34044830-E6488DDE-7768-4A81-ACA4-9221C2FD034CQ34194075-3F85E9AB-D918-4BCD-9BDE-0B61618B5FDCQ34321254-9AD8CE82-F74D-40C6-91DE-E319D373A65BQ34449957-40421BE7-EF79-4784-8EC4-93CBD1826F26Q34581022-BE2159BC-5F86-4F29-A60C-E7FE36473278Q34639532-492F6959-251A-45CC-98FE-E6E8C63B9B17Q35062693-DBCE2D02-FC5E-470A-8C71-B3DA0AB14B16Q35145922-8417D02D-2B7B-4970-A79E-AE18304B1B50Q35187734-03E46857-568A-40A0-B39C-05CA6F621B8CQ35213835-780EFA5E-14E4-4761-B91C-286F918607A8Q35475660-3E2D947A-2AB6-4FD8-B509-621BE77085B0Q35529775-D64067D5-B5C5-433A-853A-49142FAA7508Q35596369-941EADEE-EAAD-4A67-A3E3-C65EE7F3F76EQ35638401-555091E8-4042-4BD0-85D1-A28B27480987Q35788934-1142257A-60CB-4773-B040-860EB316B4EDQ36001179-3785765D-4B19-457A-BB5B-392553A3621BQ36030770-95FF73E0-3C84-4C98-9CEA-F6C9457F6C01
P2860
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
A SUMOylation-defective MITF g ...... melanoma and renal carcinoma.
@en
A SUMOylation-defective MITF g ...... melanoma and renal carcinoma.
@nl
type
label
A SUMOylation-defective MITF g ...... melanoma and renal carcinoma.
@en
A SUMOylation-defective MITF g ...... melanoma and renal carcinoma.
@nl
prefLabel
A SUMOylation-defective MITF g ...... melanoma and renal carcinoma.
@en
A SUMOylation-defective MITF g ...... melanoma and renal carcinoma.
@nl
P2093
P2860
P50
P356
P1433
P1476
A SUMOylation-defective MITF g ...... melanoma and renal carcinoma.
@en
P2093
Alain Lortholary
Annick Rossi
Arnaud de la Fouchardière
Audrey Remenieras
Benoit d'Hayer
Bertrand Bachollet
Betty Gardie
Brigitte Gilbert
Bruno Labeille
Catherine Dugast
P2860
P2888
P356
10.1038/NATURE10539
P407
P50
P577
2011-10-19T00:00:00Z